This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?

Sitagliptin — enhancing incretin action

Diabetic Department, Victoria Hospital, Kirkcaldy, KY2 5AH, Scotland, UK

Caroline Day

Diabetes Research Group, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, UK, cday{at}mededuk.com

DPP-4 inhibition offers a new approach to the treatment of type 2 diabetes. Sitagliptin is the first in this new class of agent that lowers hyperglycaemia mainly via enhancing the action of endogenous incretin hormones. Sitagliptin improves glycaemic control with a low risk of hypoglycaemia or weight gain.

Key Words: DPP-4 • gliptin • incretin • inhibitor • sitagliptin • type 2 diabetes

References

• Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pep 2005;128:87-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McIntyre N., Holdsworth CD, Turner DS New interpretation of oral glucose tolerance. Lancet 1964;2:20-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Elrick H., Stimmler L., Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.[Abstract/Free Full Text]
• Unger RH, Eisentraut AM Entero-insular axis. Arch Int Med 1969;123:261-6.[Abstract/Free Full Text]
• Marks V., Morgan L. The entero-insular axis in Recent advances in diabetes, Nattrass M, Santiago (eds) Churchill Livingstone, London 1984;1:55-71.
• Nauck M., Stockmann F., Ebert R., Creuzfeldt W. Reduced incretin effecting type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nauck MA, Heimesaat MM, Orskov C. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-07.[Web of Science][Medline] [Order article via Infotrieve]
• Estall JL, Drucker DJ Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12:1731-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Drucker DJ The biology of incretin hormones. Cell Metabolism 2006;3:153-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Drucker DJ The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Green BD, Flatt PR, Bailey CJ Dipeptidyl peptidase 4 (DPP 4) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 2006;3:159-65.[CrossRef]
• Bailey CJ Oral antidiabetic drugs. Encyclopedia of Molecular Pharmacology Offermans S, Rosenthal W (eds) Springer (in press).
• Sitagliptin, Summary of Product Characteristics http://emc.medicines.org.uk/
• Herman G., Bergman A., Wagner JA Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia 2006;49:(suppl 1) Abstract 0795.
• Hermann G., Hanefeld M., Wu M. et al. Effect of MK-0431, a dipeptidyl peptidase 4 (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005;54:Abstract 541-P.
• Nonaka K., Kakikawa T., Sato et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes. Diabetologia 2006;49(suppl1):Abstract 0038.
• Raz I., Hanefeld M., Xu L. et al. Efficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetes. Diabetologia 2006;49:(suppl 1).Abstract 0794.
• Aschner P., Kipnes M., Lunceford J. et al. Effect of the dipeptidyl peptidase-4 sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.[Abstract/Free Full Text]
• Goldstein BJ, Feinglos MN, Lunceford et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (in press), published online May 7 2007.
• Rosenstock J., Brazg R., Andryuk P. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, Clin Therapeutics 2006;28:1556-68. randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics 2006;28:1556-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nauck MA, Meininger G., Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately confonylurea, glipizide, in patients with type 2 diabete de ately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Charbonnel B., Karisik A., Liu J. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.[Abstract/Free Full Text]
• Brazg R., Xu L., Dalla Man C. et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nathan DM, Buse JB, Davidson ME et al. Management of hyperlgycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006;29:1963-72.[Free Full Text]
• Mistry G., Bergman A., Wen-Lin L. et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects. Diabetes 2006; Abstract 2001-PO.
• Ruddy MK, Bergman AJ, Zheng W. et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes 2006.Abstract 558-P.
• Vilsboll T., Knop FK DPP 4 inhibitors current evidence and future directions. Br J Diabetes Vasc Dis 2007;2:69-74.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 134-139 (2007)
DOI: 10.1177/14746514070070030601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Articles by Day, C. Search for Related Content Social Bookmarking                         What's this?